M Karabulut1, M Gunaldi2, H Alis1, C U Afsar3, S Karabulut4, M Serilmez5, C Akarsu1, H Seyit1, N F Aykan4. 1. Clinic of General Surgery, Istanbul Bakırköy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey. 2. Clinic of Medical Oncology, Istanbul Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey. 3. Department of Medical Oncology, Ministry of Health, Istanbul Training and Research Hospital, Istanbul, Turkey. cigdemusul@yahoo.com. 4. Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey. 5. Department of Basic Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey.
Abstract
INTRODUCTION: Nectins are a family of integral protein and immunoglobulin-like cell adhesion molecules involved in the formation of functioning adherence and tight junctions. Aberrant expression is associated with cancer progression, apoptosis and cell proliferation but little is known how these effects change in cell behavior. The objective of this study was to evaluate the serum levels of nectin-2 with regard to diagnostic, predictive and prognostic value in colorectal cancer (CRC) patients. MATERIALS AND METHODS: One-hundred and forty CRC patients were enrolled in this study. Serum nectin-2 levels were determined by enzyme-linked immunosorbent assay method. Age- and sex-matched 40 healthy controls were included in the analysis. RESULTS: Median age of patients was 60 years old, range 24-84 years. The localization of tumor in majority of the patients was colon (n = 81, 58 %). Non-metastatic (stage II and III) and metastatic patients' baseline serum nectin-2 levels were significantly higher than those in the healthy control group (p < 0.001; for two group). However, known clinical variables including response to CTx (chemotherapy) were not found to be correlated with serum nectin-2 concentrations (p > 0.05). While non-metastatic group patients with elevated serum nectin-2 levels showed significant adverse effect on PFS, metastatic group patients with elevated serum nectin-2 levels showed no significant adverse effect on PFS (p = 0.05 and p = 0.29, respectively). On the other hand, our study results did not show statistically significant serum nectin-2 concentrations regarding overall survival rates. CONCLUSION: Serum levels of nectin-2 may have diagnostic roles for CRC patients. Moreover, our study results show the prognostic role of nectin-2 in non-metastatic group patients.
INTRODUCTION: Nectins are a family of integral protein and immunoglobulin-like cell adhesion molecules involved in the formation of functioning adherence and tight junctions. Aberrant expression is associated with cancer progression, apoptosis and cell proliferation but little is known how these effects change in cell behavior. The objective of this study was to evaluate the serum levels of nectin-2 with regard to diagnostic, predictive and prognostic value in colorectal cancer (CRC) patients. MATERIALS AND METHODS: One-hundred and forty CRCpatients were enrolled in this study. Serum nectin-2 levels were determined by enzyme-linked immunosorbent assay method. Age- and sex-matched 40 healthy controls were included in the analysis. RESULTS: Median age of patients was 60 years old, range 24-84 years. The localization of tumor in majority of the patients was colon (n = 81, 58 %). Non-metastatic (stage II and III) and metastatic patients' baseline serum nectin-2 levels were significantly higher than those in the healthy control group (p < 0.001; for two group). However, known clinical variables including response to CTx (chemotherapy) were not found to be correlated with serum nectin-2 concentrations (p > 0.05). While non-metastatic group patients with elevated serum nectin-2 levels showed significant adverse effect on PFS, metastatic group patients with elevated serum nectin-2 levels showed no significant adverse effect on PFS (p = 0.05 and p = 0.29, respectively). On the other hand, our study results did not show statistically significant serum nectin-2 concentrations regarding overall survival rates. CONCLUSION: Serum levels of nectin-2 may have diagnostic roles for CRCpatients. Moreover, our study results show the prognostic role of nectin-2 in non-metastatic group patients.
Authors: Christoph Kahlert; Tristan Lerbs; Mathieu Pecqueux; Esther Herpel; Michael Hoffmeister; Lina Jansen; Hermann Brenner; Jenny Chang-Claude; Hendrik Bläker; Matthias Kloor; Wilfried Roth; Christian Pilarsky; Nuh N Rahbari; Sebastian Schölch; Ulrich Bork; Christoph Reissfelder; Jürgen Weitz; Daniela Aust; Moritz Koch Journal: Int J Cancer Date: 2015-05-21 Impact factor: 7.396
Authors: David Cunningham; Wendy Atkin; Heinz-Josef Lenz; Henry T Lynch; Bruce Minsky; Bernard Nordlinger; Naureen Starling Journal: Lancet Date: 2010-03-20 Impact factor: 79.321
Authors: Ece Canan Sayitoglu; Anna-Maria Georgoudaki; Michael Chrobok; Didem Ozkazanc; Benjamin J Josey; Muhammad Arif; Kim Kusser; Michelle Hartman; Tamara M Chinn; Renee Potens; Cevriye Pamukcu; Robin Krueger; Cheng Zhang; Adil Mardinoglu; Evren Alici; Harry Thomas Temple; Tolga Sutlu; Adil Doganay Duru Journal: Front Immunol Date: 2020-01-28 Impact factor: 7.561